EQ
Live price temporarily unavailable.
Price history
Equillium (EQ) is a Health Care company. Latest news and coverage below.
IPO: October 12, 2018 · $14.00 offering · NASDAQ · View IPO details →
Equillium revenue & net income history (FY2018–FY2025)
RevenueNet income
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | $15.8M | $36.1M | $41.1M | — |
| Growth (year over year) | — | — | — | — | — | +129.0% | +13.9% | — |
| Operating income | −$8.62M | −$26.7M | −$29.5M | −$37.8M | −$62.1M | −$14.5M | −$8.27M | −$23.6M |
| Operating margin | — | — | — | — | −393.9% | −40.2% | −20.1% | — |
| Net income | −$13.3M | −$25.6M | −$29.8M | −$39.1M | −$62.4M | −$13.3M | −$8.07M | −$22.4M |
| Net margin | — | — | — | — | −396.1% | −37.0% | −19.6% | — |
| EPS (diluted) | −$1.09 | −$1.47 | −$1.46 | −$1.36 | −$1.85 | −$0.38 | −$0.23 | −$0.39 |
| Balance sheet | ||||||||
| Cash and equivalents | $28.5M | $13.2M | $24.0M | $50.4M | $59.1M | $23.2M | $18.1M | $30.3M |
| Total assets | $67.2M | $55.5M | $85.4M | $85.4M | $78.4M | $50.5M | $25.6M | $31.9M |
| Total liabilities | $2.23M | $13.7M | $15.6M | $18.9M | $46.5M | $28.0M | $6.54M | $3.29M |
| Long-term debt | — | $9.68M | $8.28M | $8.75M | $3.24M | — | — | — |
| Shareholders' equity | $64.9M | $41.8M | $69.9M | $66.5M | $31.9M | $22.6M | $19.1M | $28.6M |
| Cash flow | ||||||||
| Operating cash flow | −$7.53M | −$22.9M | −$24.6M | −$32.1M | −$8.73M | −$21.8M | −$19.0M | −$22.7M |
| Capital expenditure | $35.0K | $74.0K | $202.0K | $57.0K | $279.0K | $50.0K | $85.0K | $48.0K |
| Free cash flow | −$7.56M | −$23.0M | −$24.8M | −$32.1M | −$9.01M | −$21.8M | −$19.1M | −$22.8M |
| Share buybacks | — | — | — | — | — | $260.0K | — | — |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $12.2M | $4.39M | — | — | — | — | — | — |
| Growth (year over year) | +37.1% | −52.3% | — | — | — | — | — | — |
| Operating income | −$679.0K | −$4.70M | −$8.87M | −$6.23M | −$4.58M | −$3.96M | −$5.61M | −$5.16M |
| Operating margin | −5.6% | −107.0% | — | — | — | — | — | — |
| Net income | −$7.00K | −$5.79M | −$8.65M | −$5.74M | −$4.23M | −$3.77M | −$5.31M | −$4.69M |
| Net margin | −0.1% | −131.9% | — | — | — | — | — | — |
| EPS (diluted) | $0.00 | −$0.16 | −$0.24 | −$0.16 | −$0.06 | $0.07 | −$0.06 | −$0.04 |
| Balance sheet | ||||||||
| Cash and equivalents | $15.4M | $18.1M | $14.5M | $11.5M | $33.1M | $30.3M | $61.3M | $57.2M |
| Total assets | $34.5M | $25.6M | $16.7M | $12.4M | $34.5M | $31.9M | $63.1M | $58.7M |
| Total liabilities | $11.3M | $6.54M | $6.15M | $7.34M | $3.57M | $3.29M | $3.60M | $2.65M |
| Shareholders' equity | $23.2M | $19.1M | $10.6M | $5.06M | $30.9M | $28.6M | $59.5M | $56.0M |
| Cash flow | ||||||||
| Operating cash flow | −$7.66M | −$3.30M | −$8.17M | −$3.01M | −$8.43M | −$3.13M | −$4.30M | −$4.11M |
| Capital expenditure | $0 | $4.00K | $4.00K | $0 | $0 | $44.0K | $3.00K | $71.0K |
| Free cash flow | −$7.66M | −$3.30M | −$8.17M | −$3.01M | −$8.43M | −$3.18M | −$4.30M | −$4.18M |
From Equillium's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Equillium
- Headquarters
- La Jolla, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International